Jennifer Robertson, a 59-year-old from Broughty Ferry near Dundee, has made medical history by becoming the first person in Europe to receive a personalised cancer vaccine. This innovative treatment, known as individualised neoantigen therapy, leverages the patient's immune system to combat cancer cells. The vaccine, which employs technology similar to that used in the Covid-19 mRNA vaccines, is tailored to each patient by analyzing the biological makeup of their tumors to identify potential immune system targets.
Robertson, who was diagnosed with gastro-oesophageal cancer in July, is participating in an early-stage clinical trial at the Tayside Cancer Centre, a collaboration between the University of Dundee and NHS Tayside. This trial is part of a global effort involving 38 cancer centers, with only 20 patients worldwide selected to receive this therapy during its initial phase.
The treatment involves up to nine doses of the personalised vaccine, administered alongside traditional cancer treatments such as surgery and chemotherapy. Robertson expressed her enthusiasm and gratitude for being part of this pioneering trial, stating, "I’m excited and privileged to be the first person in Europe to have this treatment, that’s really something special."
Professor Russell Petty, leading the clinical trial in Scotland, highlighted the potential of this therapy to revolutionize cancer treatment. "This therapy aims to provide a new approach to engaging the patient’s own immune system to fight their cancer," he explained. The trial not only offers hope for those with gastro-oesophageal cancer but also explores the treatment's efficacy in non-small cell lung cancer and pancreatic cancer patients.
This trial represents a significant advancement in the fight against cancer, offering a glimpse into a future where treatments are more effective, less toxic, and precisely targeted. As the trial progresses, each success brings researchers closer to transforming the landscape of cancer therapy.
